Earlier, Schreiber et al. molecularly characterized a therapy-resistant high-mesenchymal cell state across diverse tumor types and identified a distinct class of drugs targeting the phospholipid glutathione peroxidase (GPX4) as potential therapeutic targets [35,36,37,38]. The gene discussed is GPX4; the disease is neoplasm.